By a News Reporter-Staff News Editor at Clinical Oncology Week -- Data detailed on Oncology have been presented. According to news originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "The application of carmustine (BCNU) for glioma treatment is limited due to its poor selectivity for tumor and tumor resistance caused by O-6-methylguanine-DNA-methyl transferase (MGMT). To improve the efficacy of BCNU, we constructed chitosan surface-modified poly (lactide-co-glycolides) nanoparticles (PLGA/CS NPs) for targeting glioma, loading BCNU along with O-6-benzylguanine (BC), which could directly deplete MGMT."
Our news journalists obtained a quote from the research from Fudan University, "With core shell structure, PLGA/CS NPs in the diameter around 177 nm showed positive zeta potential. In vitro plasma stability of BCNU in NPs was improved compared with free BCNU. The cellular uptake of NPs increased with surface modification of CS and decreasing particle size. The cytotoxicity of BCNU against glioblastoma cells was enhanced after being encapsulated into NPs; furthermore, with the co-encapsulation of BCNU and BG into NPs, BCNU + BC PLGA/CS NPs showed the strongest inhibiting ability. Compared to free drugs, PLGA/CS NPs could prolong circulation time and enhance accumulation in tumor and brain. Among all treatment groups, F98 glioma-bearing rats treated with BCNU + BC PLGA/CS NPs showed the longest survival time and the smallest tumor size."
According to the news editors, the research concluded: "The studies suggested that the co-encapsulation of BCNU and BC into PLGA/CS NPs could remarkably enhance the efficacy of BCNU, accompanied with greater convenience for therapy."
For more information on this research see: Cationic core-shell nanoparticles with carmustine contained within O-6-benzylguanine shell for glioma therapy. Biomaterials, 2013;34(35):8968-8978. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news correspondents report that additional information may be obtained from L.L. Qian, Fudan University, Huashan Hosp, Dept. of Neurosurg, Shanghai 200040, People's Republic of China. Additional authors for this research include J.J. Zheng, K. Wang, Y. Tang, X.F. Zhang, H.S. Zhang, F.P. Huang, Y.Y. Pei and Y.Y. Jiang (see also Oncology).
Keywords for this news article include: Asia, Glioma, Therapy, Shanghai, Oncology, Treatment, Carmustine, Nanoparticle, Nanotechnology, Emerging Technologies, Nitrosourea Compounds, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC